Abbott said that the BVS study results demonstrated that they remained consistent with the six-month data from the same 45-patient group, with the rate of major adverse cardiac events (MACE) unchanged at 4.4% and no reports of blood clots (thromboses).
The BVS is made of polylactide biocompatible material that is used in medical implants such as resorbable sutures and its bioresorbable technology is designed to restore blood flow by opening a clogged vessel and providing support until it is healed.
Mercy Hospital in Auckland, New Zealand, co-principal investigator for the Absorb trial and medical director John Ormiston said that he was impressed with how consistent the BVS data have been to date, as the nine-month data are compelling and supportive of earlier positive results.
“In addition to the positive safety data we’ve seen to date, the late loss rate of 0.19mm reported at six months is comparable to a metallic drug eluting stent, and may address a limitation of metal stents by not leaving metal in the artery,” Ormiston said.
“This technology is truly a step forward for the field of interventional cardiology, and I am excited about the prospect of treating patients with this revolutionary product.”
Abbott also presented six-month results for all 101 patients enrolled in the second stage of the Absorb trial where the MACE rate remained consistent, with a nominal increase from 4.4% at six months in the first 45 patients to 5.0% at six months in all 101 patients with no reports of blood clots.
